Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Medical - Instruments & Supplies

Healthcare
$28.29 -0.37%

-$0.07 today

Market cap
$1.69B
Beta
0.83
P/E (TTM)
-6.9
EPS (TTM)
-$2.74
52W Low $13.25High $30.00

Volume 0.44M

Average 0.33M

KMTS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Kestra Medical Technologies, Ltd.NASDAQ: KMTS

Accounts Receivables · Q3 FY2026 · quarter ended Jan 2026

Accounts receivables grows, but more slowly than its trailing trend

Q3 FY2026 accounts receivables of $2.66M (cash outflow) rose 5.0% year over year, behind the +37.6% change in trailing-twelve-month accounts receivables. Sequentially, it rose 56.1% from the prior quarter.

Context

  • Accounts receivables amounted to 14.7% of revenue in FY2025, up 7.5 pp from a year earlier.
  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.0% toward the trailing-twelve-month pace of +37.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJan 2026
-$2.66M+56.1% QoQ
Last fiscal yearApr 2025
-$8.78M+339.3% YoY
LTMJan 2026
-$8.99M+37.6% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.0%——
1 year+339.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(8.78M) USD
Year-over-year change
-339.3%

Accounts Receivables vs competitors

How KMTS compares with its peers on the latest reported figures

  • KMTS's LTM Jan 2026 accounts receivables of $8.99M is the 2nd largest of the 3 companies compared; the peer median is $54.34M.
  • Its year-over-year change of +37.6% is the highest of 3, against a peer median of -36.6%.
  • Accounts receivables amounts to 10.7% of revenue for KMTS, versus a peer median of 6.4%.
KMTS Competitors Peer median
Accounts Receivables for KMTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRTCiRhythm Technologies, Inc.LTM Sep 2026$108.59M +9.0%+15.6%12.7%
KMTSKestra Medical Technologies, Ltd.LTM Jan 2026$8.99M +37.6%—10.7%
CVRXCVRx, Inc.LTM Mar 2026$92K -82.2%-22.0%0.2%
Peer median (excluding KMTS) $54.34M-36.6%-3.2%6.4%

Competitors are the stored peer set for KMTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2020
Apr 2020
FY2021
Apr 2021
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Net Income(29.47M)(34.1M)(84.24M)(94.12M)(113.81M)
Depreciation & Amortization478K420K4.86M11.56M7.97M
Deferred Income Tax00(45K)12K64K
Stock-Based Compensation01.86M1.21M1.49M24.27M
Change in Working Capital(2.01M)(19K)1.3M4.39M(6.2M)
Accounts Receivables000(2M)(8.78M)
Inventory00(733K)(1.18M)(3.44M)
Accounts Payables(790K)(132K)2.14M7.34M2.84M
Other Working Capital(1.22M)113K(112K)223K3.18M
Other Non-Cash Items706K1.94M7.28M4.44M10.11M
Operating Cash Flow(30.29M)(29.9M)(69.64M)(72.24M)(77.61M)
Capital Expenditures(232K)(336K)(15.46M)(12.51M)(23.59M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities02K0285K283K
Investing Cash Flow(232K)(334K)(15.46M)(12.23M)(23.31M)
Debt Repayment020M(5.33M)5.88M0
Common Stock Issued0000215.79M
Common Stock Repurchased00000
Dividends Paid(183K)(187K)(671K)(799K)(1.65M)
Other Financing Activities30.42M29M0(2.35M)12.73M
Financing Cash Flow30.24M48.82M96.11M77.73M330.26M
Effect of Forex Changes00000
Net Change in Cash(286K)18.59M11M(6.74M)229.35M
Free Cash Flow(30.53M)(30.23M)(85.1M)(84.75M)(101.2M)

Kestra Medical Technologies, Ltd.

NASDAQ:KMTS

Intrinsic Alpha fair value

Locked

Current Price

$28.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.